NasdaqCM - Nasdaq Real Time Price USD

Unicycive Therapeutics, Inc. (UNCY)

0.9000
+0.1456
+(19.30%)
At close: June 9 at 4:00:01 PM EDT
0.9500
+0.05
+(5.56%)
After hours: June 9 at 7:59:38 PM EDT

Key Executives

Amounts are as of December 31, 2024 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Shalabh K. Gupta M.D., MPA Founder, Chairman, CEO & President 1.12M -- 1974
Dr. Pramod Gupta Ph.D. Executive Vice President of Pharmaceutical & Business Operations 690.3k -- 1960
Mr. Douglas Jermasek M.B.A. Executive Vice President of Corporate Strategy 408.38k -- 1961
Mr. John W. Townsend CPA Chief Financial Officer 197.86k -- 1962

Unicycive Therapeutics, Inc.

4300 El Camino Real
Suite 210
Los Altos, CA 94022
United States
650 351 4495 https://unicycive.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
22

Description

Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies to address unmet medical needs in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb RZB 012 for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company also evaluates licensing of technologies and drugs for orphan diseases, other renal, liver, and other metabolic diseases affecting fibrosis and inflammation. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd to develop and commercialize oxylanthanum carbonate; Sphaera Pharma Pte. Ltd.; Syneos Health LLC to develop of UNI-494; Inotiv for preclinical trial and related services for oxylanthanum carbonate and UNI-494; Lee's Pharmaceutical (HK) Limited; and Lotus International Pte Ltd for the development, registration filing, and approval for oxylanthanum carbonate. The company was incorporated in 2016 and is based in Los Altos, California.

Corporate Governance

Unicycive Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

May 14, 2025 at 11:15 AM UTC

Unicycive Therapeutics, Inc. Earnings Date

Recent Events

June 9, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 21, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 14, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 7, 2025 at 12:00 AM UTC

DEFA14A: Proxy Statements

April 30, 2025 at 12:00 AM UTC

DEF 14A: Proxy Statements

April 14, 2025 at 12:00 AM UTC

8-K/A: Corporate Changes & Voting Matters

April 1, 2025 at 12:00 AM UTC

S-8: Offering Registrations

March 31, 2025 at 12:00 AM UTC

10-K: Periodic Financial Reports

January 7, 2025 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

November 14, 2024 at 12:00 AM UTC

SC 13G/A: Tender Offer/Acquisition Reports

Related Tickers